Founded in the year 2014 by Sujata Chaudhri and located in the National Capital Region (NCR) in India, our firm provides advisory, litigation and enforcement, and prosecution services in all areas of intellectual property law.
Recently, in an appeal filed by the appellant, Karan Rathore, the Delhi High Court overturned an order passed by the Trade Marks Registry (“Registry”) dismissing an opposition filed by the appellant against an application filed by the respondent, Shivam Rathore. The appellant is the registered owner of the mark JBR Device, which covers motor parts in Class 12. In July 2020, the appellant’s predecessor-in-interest formally authorized the respondent to use the appellant’s mark
The Delhi High Court has handed down an important decision in Alkem Laboratories Ltd. v. Prevego Healthcare & Research Pvt. Ltd. , observing that device marks cannot automatically grant protection over the word or letters comprised therein, unless shown to have acquired secondary meaning. The court held that a registration for a device of the mark ‘A TO Z’ will not offer protection against use of the marks “A TO Z” or “AZ”, since these would be inherently descriptive. The
Semaglutide is the rare drug that sits at the intersection of science, culture and capital. The Delhi High Court’s semaglutide order in CS(COMM) 565/2025 Novo Nordisk v Dr Reddy’s shows how Indian courts will police the outer edge of that capital: the extra years companies try to add through follow‑on patents. Novo’s enforcement hinged on a later “species” patent, IN262697, claiming semaglutide as a specific GLP‑1 analogue. An older “genus” patent, IN275964, had already cl
